New Zealand markets closed

Shanghai Junshi Biosciences Co., Ltd. (1877.HK)

HKSE - HKSE Delayed price. Currency in HKD
Add to watchlist
17.480-1.120 (-6.02%)
At close: 04:08PM HKT

Shanghai Junshi Biosciences Co., Ltd.

Building 7
15th Floor No.6, Lane 100, Pingjiaqiao Road Pudong New Area
Shanghai 200126
86 21 6105 8800

Full-time employees2,772

Key executives

NameTitlePayExercisedYear born
Mr. Jun XiongExec. ChairmanN/AN/A1974
Dr. Ning LiCo-CEO, GM & Exec. DirectorN/AN/A1962
Mr. Cong LiCo-CEO & Exec. DirectorN/AN/A1964
Mr. Baohong XuFinancial DirectorN/AN/A1979
Mr. Zhuobing ZhangDeputy GM & Exec. DirectorN/AN/A1968
Dr. Sheng YaoSr. VP & Exec. DirectorN/AN/A1976
Mr. Gang WangChief Quality Officer & Sr. VP of Industry AffairsN/AN/A1957
Dr. Jianjun ZouDeputy GM, Global R&D Pres and Exec. DirectorN/AN/A1972
Ms. Yingge ChenJoint Company Sec.N/AN/A1992
Ms. Lu YuanAssistant to GM & Chief of Internal Audit DepartmentN/AN/A1982
Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.


Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, nervous system, and infectious diseases in the People's Republic of China. The company was founded in 2012 and is headquartered in Shanghai, People's Republic of China.

Corporate governance

Shanghai Junshi Biosciences Co., Ltd.’s ISS governance QualityScore as of 28 September 2023 is 6. The pillar scores are Audit: 6; Board: 6; Shareholder rights: 9; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.